Lens Wear Schedules and End-of-Day Comfort (INVERMERE)

This study has been completed.

Sponsor:

Collaborator:

University of Waterloo

Information provided by (Responsible Party):

Alcon Research ( CIBA VISION )

ClinicalTrials.gov Identifier:

NCT01433549

First received: September 12, 2011

Last updated: April 30, 2013

Last verified: April 2013

History of Changes

Results First Received: March 20, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Single Blind (Subject); Primary Purpose: Supportive Care
Condition:	Myopia
Interventions:	Device: Lotrafilcon B Device: Senofilcon A

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from one study center located in Canada.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of the 44 participants enrolled, 16 were exited from the study prior to randomization (screen failures). Three subjects were randomized/fitted with lenses but discontinued prior to product dispense. This reporting group includes all participants enrolled and dispensed product. A 12-hour lens-free wear period preceded each phase.

Reporting Groups

	Description
Lotrafilcon B / Senofilcon A	Lotrafilcon B worn first, with senofilcon A worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
Senofilcon A / Lotrafilcon B	Senofilcon A worn first, with lotrafilcon B worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).

Participant Flow for 2 periods

Period 1: Phase 1: First Study Product

	Lotrafilcon B / Senofilcon A	Senofilcon A / Lotrafilcon B
STARTED	12	13
COMPLETED	12	13
NOT COMPLETED	0	0

Period 2: Phase 2: Second Study Product

	Lotrafilcon B / Senofilcon A	Senofilcon A / Lotrafilcon B
STARTED	12	13
COMPLETED	12	12
NOT COMPLETED	0	1
Adverse Event	0	1

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Overall	Lotrafilcon B and Senofilcon A worn in cross-over fashion as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).

Baseline Measures

	Overall
Number of Participants [units: participants]	25
Age, Customized [units: years] Median ( Full Range )	25 ( 19 to 43 )
Gender [units: participants]
Female	15
Male	10
Region of Enrollment [units: participants]
Canada	25

Outcome Measures

Show All Outcome Measures

1. Primary:

Mean End-of-Day Comfort [ Time Frame: Hour 12 ]

Show Outcome Measure 1

2. Secondary:

Mean Non-Invasive Tear Film Break-Up Time (NITBUT) [ Time Frame: Hour 12 ]

Show Outcome Measure 2

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: R. Alan Landers, O.D., M.S., F.A.A.O.
Organization: Alcon Research, Ltd.
phone: 1-888-451-3937
e-mail: alcon.medinfo@alcon.com

No publications provided

Responsible Party:	Alcon Research ( CIBA VISION )
ClinicalTrials.gov Identifier:	NCT01433549 History of Changes
Other Study ID Numbers:	P-373-C-104
Study First Received:	September 12, 2011
Results First Received:	March 20, 2013
Last Updated:	April 30, 2013
Health Authority:	Canada: Ethics Review Committee

To Top